Mersana Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2020 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs
August 31, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer
August 11, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update
August 07, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
- Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate...
Mersana Therapeutics to Present at Upcoming Investor Conferences
August 04, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates
July 31, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting
June 22, 2020 09:05 ET
|
Mersana Therapeutics, Inc.
Preclinical data on XMT-1592, a NaPi2b-targeted site-specific and homogeneous Dolasynthen ADC, demonstrate excellent activity, tolerability and pharmacokineticsPreclinical data on multiple...
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 02, 2020 17:24 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
May 28, 2020 23:24 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...